About Us
Overview
Company Milestones
Our Facilities
Products
Medical Information
Contact Us
About Us
Overview
Company Milestones
Our Facilities
Products
Medical Information
Contact Us
2014 – Zydus launched world’s first biosimilar of adalimumab
Post navigation
Previous:
2013 – Received USFDA approval for initiating Phase I clinical trials of ZYDPLA1, a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes
Next:
2015 – Zydus began Phase III study of saroglitazar in NASH